Evidence map›Paper›PMID 38323838›Full record

ArticleJournal of acquired immune deficiency syndromes (1999)2024

Differentiated service delivery framework for people with multidrug-resistant tuberculosis and HIV co-infection.

Karl Reis, Allison Wolf, Rubeshan Perumal, Boitumelo Seepamore, Kevin Guzman, Jesse Ross, Ken Cheung, K Rivet Amico, James C M Brust, Nesri Padayatchi and 5 more

Open access · greenAbstract read
In one paragraph

Article in Journal of acquired immune deficiency syndromes (1999), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 citations in OpenAlex.

  1. Article
  2. Article
  3. Differentiated service delivery for TB treatment.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2026
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 7 institutions in 3 countries.

Karl ReisVagelos College of Physicians and Surgeons, Columbia University, New York City, NY.ORCID 0000-0002-9509-4526
Allison WolfDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York City, NY.
Rubeshan PerumalCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
Boitumelo SeepamoreCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
Kevin GuzmanDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York City, NY.
Jesse RossDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York City, NY.
Ken CheungDepartment of Biostatistics, Columbia University Irving Medical Center, New York City, NY.
K Rivet AmicoUniversity of Michigan School of Public Health, Ann Arbor, MI.
James C M BrustDivisions of General Internal Medicine and Infectious Diseases, Department of Medicine, Albert Einstein College of Medicine, Bronx, NY.
Nesri PadayatchiCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
Gerald FriedlandDepartment of Medicine (Infections Diseases), Yale University School of Medicine, New Haven, CT.
Kogieleum NaidooCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
Amrita DaftaryCAPRISA MRC- HIV-TB Pathogenesis and Treatment Research Unit, Durban, South Africa.
Jennifer ZelnickGraduate School of Social Work, Touro University, New York City, NY.
Max O'DonnellDivision of Pulmonary, Allergy, and Critical Care Medicine, Columbia University Irving Medical Center, New York City, NY.
South African Medical Research Council · ZAColumbia University Irving Medical Center · USAlbert Einstein College of Medicine · USCity University of New York · USColumbia University · USUniversity of Michigan · USYale University · US

Funding

The Columbia University Training Program in Lung ScienceT32HL105323 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Jahar Bhattacharya, Wellington V. Cardoso · 2011 to 2026
$4.7M
Adaptive evaluation of mHealth and conventional adherence support interventions to optimize outcomes with new treatment regimens for drug-resistant tuberculosis and HIV in South AfricaR01AI167795 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Max O'Donnell · 2022 to 2026
$2.9M
Promoting Engagement in the Drug Resistant TB/HIV Care Continuum in South AfricaR01AI124413 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI O'DONNELL, MAX, PADAYATCHI, NESRI · 2016 to 2020
$2.7M
Mentoring of multidisciplinary global health research in tuberculosis and HIVK24AI155045 · NIAID · ALBERT EINSTEIN COLLEGE OF MEDICINE · PI BRUST, JAMES C M · 2020 to 2025
$889k
Medical Research Council MC_PC_16022NHLBI NIH HHS T32 HL105323NIAID NIH HHS K24 AI155045NIAID NIH HHS R01 AI124413NIAID NIH HHS R01 AI167795
6 · The paper itself

Abstract

introductionFor people living with HIV/AIDS, care is commonly delivered through Differentiated Service Delivery (DSD). Although people with multidrug-resistant tuberculosis (MDR-TB) and HIV/AIDS experience severe treatment associated challenges, there is no DSD model to support their treatment. In this study, we defined patterns of medication adherence and characterized longitudinal barriers to inform development of an MDR-TB/HIV DSD framework.

methodsAdults with MDR-TB and HIV initiating bedaquiline (BDQ) and receiving antiretroviral therapy (ART) in KwaZulu-Natal, South Africa, were enrolled and followed through the end of MDR-TB treatment. Electronic dose monitoring devices (EDM) measured BDQ and ART adherence. Longitudinal focus groups were conducted and transcripts analyzed thematically to describe discrete treatment stage-specific and cross-cutting treatment challenges.

results283 participants were enrolled and followed through treatment completion (median 17.8 months [IQR 16.5-20.2]). Thirteen focus groups were conducted. Most participants (82.7%, 234/283) maintained high adherence (mean BDQ adherence 95.3%; mean ART adherence 85.5%), but an adherence-challenged subpopulation with <85% cumulative adherence (17.3%, 49/283) had significant declines in mean weekly BDQ adherence from 94.9% to 39.9% (p<0.0001) and mean weekly ART adherence from 83.9% to 26.6% (p<0.0001) over 6 months. Psychosocial, behavioral, and structural obstacles identified in qualitative data were associated with adherence deficits in discrete treatment stages, and identified potential stage specific interventions.

conclusionA DSD framework for MDR-TB/HIV should intensify support for adherence-challenged subpopulations, provide multi-modal support for adherence across the treatment course and account for psychosocial, behavioral, and structural challenges linked to discrete treatment stages.

Indexed as

Antitubercular AgentsCoinfectionDelivery of Health CareHIV InfectionsTuberculosis, Multidrug-ResistantAdultAnti-HIV AgentsDiarylquinolinesFemaleFocus GroupsHumansMaleMedication AdherenceMiddle AgedSouth AfricaAnti-HIV AgentsAntitubercular AgentsbedaquilineDiarylquinolines

Identifiers

PMID38323838
PMCPMC11300702
OpenAlexW4391600257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.